Evidence map›Paper›PMID 25691643›Full record

ArticleAntimicrobial agents and chemotherapy2015

Analysis of ganciclovir-resistant human herpesvirus 6B clinical isolates using quenching probe PCR methodology.

Hiroyuki Hiramatsu, Ryota Suzuki, Shigeki Yamada, Masaru Ihira, Yuji Isegawa, Yoshiki Kawamura, Erina Matsuoka, Hiroki Miura, Tetsushi Yoshikawa

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Hiroyuki HiramatsuDepartment of Clinical Pharmacy, Fujita Health University Hospital, Aichi, Japan.
Ryota SuzukiDepartment of Clinical Pharmacy, Fujita Health University Hospital, Aichi, Japan.
Shigeki YamadaDepartment of Clinical Pharmacy, Fujita Health University Hospital, Aichi, Japan.
Masaru IhiraFaculty of Clinical Engineering, Fujita Health University School of Health Sciences, Aichi, Japan.
Yuji IsegawaDepartment of Food Sciences and Nutrition, Mukogawa Women's University School of Human Environmental Sciences, Aichi, Hyogo, Japan.
Yoshiki KawamuraDepartment of Pediatrics, Fujita Health University School of Medicine, Aichi, Japan.
Erina MatsuokaDepartment of Pediatrics, Fujita Health University School of Medicine, Aichi, Japan.
Hiroki MiuraDepartment of Pediatrics, Fujita Health University School of Medicine, Aichi, Japan.
Tetsushi YoshikawaDepartment of Pediatrics, Fujita Health University School of Medicine, Aichi, Japan tetsushi@fujita-hu.ac.jp.
Fujita Health University · JPFujita Health University Hospital · JPMukogawa Women's University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quenching probe PCR (QP-PCR) analysis was used to determine the frequency of ganciclovir (GCV) resistance among clinical isolates of human herpesvirus 6B (HHV-6B) obtained from patients with primary viral infection and viral reactivation. Forty-two HHV-6B clinical isolates were repeatedly recovered from 15 hematopoietic stem cell transplant (HSCT) recipients, and 20 isolates were recovered from 20 exanthem subitum (ES) patients. Of the 15 HSCT recipients, 9 received GCV during the observation period; however, none of the ES patients were treated with GCV. Two established laboratory strains, Z29 and HST, were used as standards in this study. Regions 1 and 2 of the U69 gene of all of the clinical isolates demonstrated the same melting temperature as regions 1 and 2 of the Z29 strain. For region 3, the melting temperatures of all clinical isolates fell between the melting temperature of the plasmid containing the A462D single nucleotide polymorphism (SNP) and the melting temperature of the Z29 strain, and the melting temperatures profiles of all clinical isolates were similar to the melting temperature profile of the Japanese HST strain. As expected, none of the 20 clinical isolates recovered from the ES patients and the 14 isolates recovered from the HSCT recipients who did not receive GCV treatment carried the six known SNPs associated with GCV resistance. Interestingly, these six SNPs were not detected in the 28 clinical isolates recovered from the 9 HSCT recipients who received GCV. Additional sequence analysis of the U69 gene from the 15 representative isolates from the 15 HSCT recipients identified other SNPs. These SNPs were identical to those identified in the HST strain. Therefore, the rate of emergence of GCV-resistant HHV-6B strains appears to be relatively low, even in HSCT recipients treated with GCV.

Indexed as

Polymerase Chain ReactionAdolescentAdultDrug Resistance, ViralFemaleGanciclovirHerpesvirus 6, HumanHumansMaleMiddle AgedPolymorphism, GeneticYoung AdultGanciclovir

Identifiers

PMID25691643
PMCPMC4394808
OpenAlexW2081204327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.